The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats

To assess the impact of concomitant inhibition of sodium-glucose cotransporter (SGLT) 2 and dipeptidyl peptidase IV (DPP4) for the treatment of type 2 diabetes mellitus (T2DM), the effect of combined treatment with canagliflozin, a novel SGLT2 inhibitor, and teneligliptin, a DPP4 inhibitor, on gluco...

Full description

Bibliographic Details
Main Authors:	Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Yoshida, Satoko Kiuchi, Yuka Ikenaga, Yoshinobu Nakamaru, Kumiko Hikida, Akira Saito, Kenji Arakawa, Kozo Oka, Kiichiro Ueta, Masaharu Shiotani
Format:	Article
Language:	English
Published:	Elsevier 2015-04-01
Series:	Journal of Pharmacological Sciences
Subjects:	Canagliflozin Teneligliptin Combination treatment Glucagon-like peptide-1 Zucker diabetic fatty rats
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861315000687

Similar Items

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
by: Takahiro Ozutsumi, et al.
Published: (2020-03-01)

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
by: Takahiro Oguma, et al.
Published: (2016-12-01)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
by: Tanya Tandon, et al.
Published: (2019-01-01)

Renoprotective effects of teneligliptin: An observational study
by: Prabhat Agrawal, et al.
Published: (2021-01-01)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
by: Erande S, et al.
Published: (2019-06-01)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
by: Okuda Y, et al.
Published: (2016-04-01)

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Crystal structure of canagliflozin hemihydrate
by: Kai-Hang Liu, et al.
Published: (2016-05-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
by: Jin-Woo Park, et al.
Published: (2021-08-01)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
by: Munehiro Kitada, et al.
Published: (2019-05-01)

Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: A randomized, double-blind study
by: Piyush Agarwal, et al.
Published: (2018-01-01)

Teneligliptin-induced hair loss: A case report
by: Prabhat K Agrawal, et al.
Published: (2020-01-01)

Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury
by: Zhen Zhang, et al.
Published: (2019-01-01)

Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin
by: David Papadopoli, et al.
Published: (2021-04-01)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
by: Ghazaleh Behnammanesh, et al.
Published: (2019-04-01)

Investigation of Solubility Behavior of Canagliflozin Hydrate Crystals Combining Crystallographic and Hirshfeld Surface Calculations
by: Yefen Zhu, et al.
Published: (2021-01-01)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
by: Katherine M. Wang, et al.
Published: (2021-07-01)

Analise morfologica, biomecanica e bioquimica de tendão de ratos Zucker (fa/fa) obesos
by: Biancalana, Adriano
Published: (2009)

Canagliflozin review – safety and efficacy profile in patients with T2DM
by: Jakher H, et al.
Published: (2019-02-01)

Efficacy and safety of canagliflozin in kidney transplant patients
by: Mita Shah, et al.
Published: (2019-01-01)

Investigation of adipose tissues in Zucker rats using in vivo and ex vivo magnetic resonance spectroscopy
by: Elisa Mosconi, et al.
Published: (2011-02-01)

Effects of conjugated linoleic acid isomers on eicosanoid metabolism in kidney and liver tissues of obese zucker rats
by: Shi, Hong
Published: (2011)

Effects of conjugated linoleic acid isomers on eicosanoid metabolism in kidney and liver tissues of obese zucker rats
by: Shi, Hong
Published: (2011)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
by: Νarjes Nasiri-Ansari, et al.
Published: (2018-07-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

Coenzyme A and Its Thioester Pools in Obese Zucker and Zucker Diabetic Fatty Rats
by: Shigeru Chohnan, et al.
Published: (2020-02-01)

Cardiovascular Changes Related to Metabolic Syndrome: Evidence in Obese Zucker Rats
by: Ilenia Martinelli, et al.
Published: (2020-03-01)

Klotho and Aminopeptidases as Early Biomarkers of Renal Injury in Zucker Obese Rats
by: Sebastián Montoro-Molina, et al.
Published: (2018-11-01)

Treinamento físico aeróbio previne à hipertrofia cardíaca patológica e melhora a função diastólica em ratos Zucker obesos Aerobic exercise training revert pathologic cardiac hypertrophy and improves the diastolic function in obese Zucker rats
by: Diego Lopes Mendes Barretti, et al.
Published: (2011-12-01)

Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
by: Ghazaleh Behnammanesh, et al.
Published: (2020-05-01)

Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
by: Sangeeta R. Kashyap, et al.
Published: (2020-06-01)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
by: Takayasu Ideta, et al.
Published: (2015-12-01)

Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain
by: Yaswanth Kuthati, et al.
Published: (2021-09-01)

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
by: Juan J. Gorgojo-Martínez, et al.
Published: (2020-07-01)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xiaoxuan Li, et al.
Published: (2018-05-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
by: Takahara M, et al.
Published: (2020-11-01)

Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
by: Yoshinori Watanabe, et al.
Published: (2015-01-01)